Nicola Gökbuget, MD
Nearly 80% of patients assigned to blinatumomab (Blincyto) for minimal residual disease (MRD)-positive acute lymphoblastic leukemia (ALL) in hematologic complete remission (CR) achieved complete MRD response, according to results from a phase II study.
Eighty-eight of 113 (78%) evaluable patients in the study had a complete MRD response after 1 cycle of treatment with blinatumomab. Two more patients achieved a complete MRD response after cycle 2; no additional patient achieved a complete MRD response after cycle 3 or cycle 4. Among 5 patients with Philadelphia chromosome (Ph)–positive disease who had MRD evaluations, 3 (60%) had an MRD response during cycle 1.
Furthermore, investigators found that complete MRD response was associated with significantly improved survival. Compared with nonresponders, the patients who had complete MRD response had superior relapse-free survival (RFS; 23.6 vs 5.7 months; P
= .002) and overall survival (OS; 38.9 vs 12.5 months; P
Among the entire study population (N = 116), median OS was 36.5 months (95% CI, 19.2-not estimable).
“Treatment of patients with persistent chemotherapy-resistant disease after conventional treatment remains a major challenge in the management of pediatric and adult ALL, with high relapse rates during continued chemotherapy and even after subsequent hematopoietic stem cell transplantation (HSCT),” Nicola Gökbuget, MD, Universitätsklinikum Frankfurt Main Medizinische Klinik II, Frankfurt, Germany, and colleagues wrote.
“Among patients with chemotherapy-resistant MRD, targeted immunotherapy with blinatumomab resulted in a substantial molecular response rate and improved long-term outcomes among responders compared to nonresponders. Our results suggest that targeted treatment at early stages of MRD is a viable therapeutic strategy for patients with B-cell precursor ALL, and that it should also be evaluated in other hematologic malignancies.”
Investigators working at 46 medical centers in Europe and Russia enrolled patients into this open-label, single-arm study from November 2010 to February 2014. Patients received 15 μg/m2 of blinatumomab daily by continuous intravenous infusion for up to 4 cycles. Each cycle comprised 4 weeks of blinatumomab infusion followed by a 2-week treatment-free period. Patients could receive HSCT any time after cycle 1 at the investigator’s discretion.
Adult patients with B-cell precursor ALL in first or later hematologic CR and with persistent or recurrent MRD ≥10−3
after a minimum of 3 blocks of intensive chemotherapy were eligible for inclusion. Median age was 45 years (range, 18-76). At baseline, 47% of patients had MRD ≥10−2
and 35% were in second or later hematologic CR.
All patients completed the treatment period. Overall, 76 patients received HSCT in continuous CR after 1 cycle.
Investigators assessed the primary endpoint of complete MRD response after 1 cycle of blinatumomab in the primary endpoint full analysis set of patients with evaluable MRD markers (n = 113). Secondary endpoints of OS, RFS, and duration of hematologic remission were analyzed in the secondary endpoint full analysis set (n = 110). Overall MRD response was evaluated in the primary endpoint efficacy set (n = 103).
The primary endpoint efficacy set for analysis of overall MRD included 103 patients with hematologic CR and MRD >10−3
at baseline. Of these, 87% achieved any MRD response, including 80% (95% CI, 71-87) with a complete MRD response after cycle 1. Complete MRD response rates were similar between patients with MRD ≥10−2
at baseline, and between patients with first or later remission at baseline. Of 45 patients in this analysis set with treatment interruptions due to any cause during cycle 1, 82% achieved a complete MRD response.
Among the 110 patients from the full analysis set who had Ph-negative disease and <5% blasts at baseline, the Kaplan-Meier estimate for RFS was 54% (95% CI, 33-70) at 18 months, exceeding the prespecified boundary of 28%. Estimates for RFS at 18 months were similar with or without censoring for post-blinatumomab HSCT and chemotherapy.
The median RFS was 18.9 months (95% CI, 12.3-35.2) at a median follow-up of 29.9 months. Median RFS was 11.0 months among patients treated within later CR versus 24.6 months for those treated in first CR (hazard ratio [HR], 2.09; 95% CI, 1.26-3.48; P
All patients who started cycle 1 experienced at least 1 adverse event (AE). One-third reported grade 3 AEs and 27% reported grade 4 AEs. Investigators considered 29% of grade 3 AEs and 22% of grade 4 AEs to be treatment-related. Four (3%) patients experienced cytokine release syndrome—2 grade 1 events and 2 grade 3 events, all during cycle 1.